Legacy Capital Group California, Inc. Gilead Sciences, Inc. Transaction History
Legacy Capital Group California, Inc.
- $328 Billion
- Q4 2024
A detailed history of Legacy Capital Group California, Inc. transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Legacy Capital Group California, Inc. holds 6,027 shares of GILD stock, worth $647,962. This represents 0.17% of its overall portfolio holdings.
Number of Shares
6,027
Previous 6,062
0.58%
Holding current value
$647,962
Previous $508 Million
9.54%
% of portfolio
0.17%
Previous 0.17%
Shares
8 transactions
Others Institutions Holding GILD
# of Institutions
2,101Shares Held
1.02BCall Options Held
8.73MPut Options Held
9.63M-
Black Rock Inc. New York, NY121MShares$13 Billion0.19% of portfolio
-
Vanguard Group Inc Valley Forge, PA116MShares$12.4 Billion0.19% of portfolio
-
Capital World Investors Los Angeles, CA71.7MShares$7.71 Billion1.05% of portfolio
-
State Street Corp Boston, MA60.4MShares$6.49 Billion0.23% of portfolio
-
Capital Research Global Investors Los Angeles, CA57.9MShares$6.23 Billion1.15% of portfolio
About GILEAD SCIENCES, INC.
- Ticker GILD
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 1,253,369,984
- Market Cap $135B
- Description
- Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...